Trade-Ideas: Cellectis (CLLS) Is Today's Weak On High Relative Volume Stock
Trade-Ideas LLC identified
(
) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Cellectis as such a stock due to the following factors:
- CLLS has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $2.9 million.
- CLLS has traded 60,123 shares today.
- CLLS is trading at 2.95 times the normal volume for the stock at this time of day.
- CLLS is trading at a new low 4.00% below yesterday's close.
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in CLLS with the Ticky from Trade-Ideas. See the FREE profile for CLLS NOW at Trade-Ideas
More details on CLLS:
Cellectis S.A., a gene-editing company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Currently there are 6 analysts that rate Cellectis a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for Cellectis has been 132,000 shares per day over the past 30 days. Cellectis has a market cap of $945.2 million and is part of the health care sector and drugs industry. Shares are down 13.9% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Cellectis as a
. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.
Highlights from the ratings report include:
- CELLECTIS SA has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. For the next year, the market is expecting a contraction of 261.4% in earnings (-$2.35 versus -$0.65).
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 608.4% when compared to the same quarter one year ago, falling from $6.60 million to -$33.56 million.
- The revenue fell significantly faster than the industry average of 19.4%. Since the same quarter one year prior, revenues fell by 12.2%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
- Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 26.31%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 605.26% compared to the year-earlier quarter.
- Compared to other companies in the Biotechnology industry and the overall market, CELLECTIS SA's return on equity significantly trails that of both the industry average and the S&P 500.
- You can view the full Cellectis Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.